Drug Profile
Research programme: alcohol dehydrogenase inhibitors - Gilead Sciences
Alternative Names: CVT-10216Latest Information Update: 15 Mar 2010
Price :
$50
*
At a glance
- Originator CV Therapeutics
- Developer Gilead Sciences
- Class Benzoic acids; Benzopyrans; Sulfonamides
- Mechanism of Action Aldehyde dehydrogenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alcoholism
Most Recent Events
- 17 Apr 2009 CV Therapeutics has been acquired and merged into Gilead Sciences